Protagonist Therapeutics, Inc.

Ionis licensed global rights to Phase II polycythemia vera (PV) candidate sapablursen to Ono Pharmaceutical on 11 March. The deal provides near-term and longer-term revenue for a drug candidate the an

More positive data on icotrokinra have lent support to Johnson & Johnson’s claim that its first-in-class oral therapy has to potential to set a new standard of treatment in plaque psoriasis. At a

Takeda Pharmaceutical envisions a potentially significant market in polycythemia vera (PV) for rusfertide, which it is developing together with Protagonist Therapeutics, after reporting positive Phase

Johnson & Johnson is preparing regulatory submissions for icotrokinra, its first-in-class oral therapy for psoriasis, after the drug hit its main goals in two Phase III studies. Icotrokinra, a onc